In vivo administration of IL-4 induces TGF-beta-producing cells and protects animals from experimental autoimmune encephalomyelitis.
Inobe
J I
JI
Center for Neurological Diseases, Harvard Medical School, Boston, Massachusetts 02115, USA.
Chen
Y
Y
Weiner
H L
HL
D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D018928:Immunity, Mucosal; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000096:biosynthesis; D016753:Interleukin-10 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000008:administration & dosage / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D051379:Mice; D008815:Mice, Inbred Strains; D004676:Myelin Basic Protein / Q000008:administration & dosage / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000096:biosynthesis*
D004676:Myelin Basic Protein; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; D015847:Interleukin-4; D007371:Interferon-gamma